comparemela.com

Page 8 - Zacks Medical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -2,300% and 85.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 6.90% and 3.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Merus N V (MRUS) Reports Q2 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of 23.26% and 0.89%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.